Contact
11 rue aristide bergès
38800 LE PONT-DE-CLAIX
France
Key Account Manager
About us
BD Group is one of the five largest medical technology companies in the world, a ranking that reflects our unwavering commitment to excellence and innovation in healthcare.
BD Biosciences, a division specializing in cytometry and single-cell multi-omics, offers you comprehensive, innovative, and efficient solutions for cell characterization and analysis. We support our clients throughout their bioproduct development process, from discovery to commercialization, ensuring efficiency at every stage, thanks to our product pipeline tailored to each of these stages.
Business offer
Solutions, CE IVD-R, cGMP, 21 CFR Part 11 approved:
- * Instruments: BD FACS LYRIC and BD FACS DUET
- * Reagents: CE-IVDR antibodies and fluorochromes
RUO Solutions :
- * Cytometry: cell sorting and analysis
* Recent innovations: FACS Discover S8 and FACS Discover A8, high- throughput spectral range with real-time integrated imaging
* Conventional instruments: FACS Melody, FACS Symphony A1, etc.
- * Single-cell multi-omics: BD Rhapsody
- * Reagents: RUO antibodies and fluorochromes, Abseq
Software : Flowjo, Infincyt, FACS Workflow Manager
Services : panel design, cytometry training, continuing education webinars
Activities
- Technology Supplier
- Genetic Diseases
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Inflammation
- Target selection & validation
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Research exploratory companion biomarkers
- Hit discovery
- Screening & Identification
- Therapeutic libraries
- In silico
- In-vivo models
- In-vitro & ex-vivo models
- Indication searching
- Bioinformatics prediction & analysis
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- Safety
- PK/PD features
- Indication Identification
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- Research exploratory Companion biomarkers
- Bioinformatics design
- Bioinformatics prediction & analysis
- Animal biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Quality assurance, quality control & analytical process
- Stability Assessment
- Physical & chemical profile
- Shear/shaking
- Viscosity
- Photostability
- pH
- Freeze/thaw
- Heat/degradation
- Aggregation
- Cell line analytical development
- Host cell proteins
- Viral clearance
- Contaminants detection
- Biosafety & Bioanalysis
- Toxicology
- Non-clinical safety and toxicology studies
- PK/PD features
- Impurities detection
- Bioproduction analytical test
- Monitoring
- Characterization
- Batch consistency
- Batch release test
- Chemical, physical, biological test
- Quality control test support
- Post-production test
- Real-time stability test
- Clinical trials
- Phase I
- Phase II
- Phase III
- Phase IV
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Safety
- PK/PD features
- Surrogate markers
- Disease progression monitoring
- Companion biomarkers
- Pharmacology
- Treatment efficacy
- Treatment monitoring
- Toxicity
- Target cell isolation
- iPS reprogramming
- Differentiated Cell
- Production Cell
- Safety donor-derived therapies
- Cell modification
- Direct reprogramming
- Cell Activation
- CMC/analytical quality assessment, quality control
- Cleaning
- Non-clinical safety and toxicology studies
- Bioproduction engineering
- CGMP
- Target Identification
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Research exploratory companion biomarkers
- Biomarker Identification
- Research exploratory Companion biomarkers
- CAR Construction
- Intracellular Domain
- T-cell activation/transduction
- Adoptive T Cell Major Challenges in Solid Tumors
- Tumor/Ag heterogeneity
- Tumor associated Antigen
- Persistence of CAR-T
- In vivo proliferation and activation of CAR-T
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Quality control
- Non-clinical safety and toxicology studies
- Antigen identification, selection, optimization, and validation
- Omics analysis
- Antigen characterization
- Antigen optimization:
- Early purification
- Antigen selection: pathogen sequencing and functional antigens
- Membrane antigens
- Outer-membrane proteins (OMP), toxins
- Internal protein
- Less immunogenic
- Conservative sequence
- Immunogenicity in relevant animal models
- Antigen-protective immune-response profile
- Humoral response characterization:
- Antibody dosage
- Functional antibody assays (neutralization, CDC, ADCC)
- Other serological assays
- Cell mediated immunity response
- T cell assays
- Reactogenicity Assessment
- Research exploratory biomarkers
- efficiency vaccination
- protection correlation
- Vaccine: antigen format platforms
- Recombinant protein expression
- Bacterial
- Cell
- Fungi
- Synthetic Peptides or oligomers
- Challenge test – Gold Standard
- Induced immune response characterization
- Regulatory safety
- Immunotoxicology
- Non-clinical safety and toxicology studies
- Clinical trials
- Phase I
- Phase II (human challenge trials)
- Phase III (large population pending pathogen prevalence)
- Immune monitoring
- Quality control & analytical process monitoring
- Biosafety & Bioanalysis
- Toxicology
- Immune response characterization
- Viral safety
- Post-market surveillance
- Clinical Trial phase IV
